KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for Emergent BioSolutions (EBS) over the last 11 years, with Q2 2024 value amounting to $27.2 million.

  • Emergent BioSolutions' Asset Writedowns and Impairment fell 9113.14% to $27.2 million in Q2 2024 from the same period last year, while for Jun 2025 it was $27.2 million, marking a year-over-year decrease of 9185.38%. This contributed to the annual value of $27.2 million for FY2024, which is 9113.14% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Asset Writedowns and Impairment of $27.2 million as of Q2 2024, which was down 9113.14% from $306.7 million recorded in Q2 2023.
  • Over the past 5 years, Emergent BioSolutions' Asset Writedowns and Impairment peaked at $306.7 million during Q2 2023, and registered a low of $27.2 million during Q2 2024.